-
In the vulvar vestibulitis clinical trial conducted at the University of Rochester between 2002 and 2007, patients with vulvar vestibulitis syndrome (localized provoked vulvodynia) were enrolled in a 12-week randomized, placebo-controlled treatment trial.
-
-
Over the years, different tocolytics have been in vogue, only to be discarded later because meta-analyses showed that the agent simply did not work. This month's review will focus on nifedipine, a medication that has been in and out of favor for more than 20 years.
-
This publication is an update on osteoporosis screening from the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation.
-
Although the annual incidence of all gynecological malignancies remains between 75,000 and 80,000, a far greater number of women with this history are survivors.
-
In this issue: Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions.
-
In a multinational observational study, independent from pharmaceutical support and involving both academic and community treatment centers, long-term follow-up for chronic myelogenous leukemia (CML) patients who, after two years of imatinib therapy, were in complete cytogenetic remission was undertaken for a median of 5.8 years. Although side effects were common, only a very small percentage of patients discontinued the drug and the majority maintained their cytogenetic response. In fact, the incidence of second malignancies and overall survival were no different for the CML patients in this cohort than for the general population in Italy.
-
Limited data are available to guide the decision between up-front allogeneic hematopoietic cell transplantation (HCT) or imatinib on long-term outcomes for accelerated phase chronic myelogenous leukemia (CML).
-
A 71-year-old retired police officer was admitted through the emergency room with right upper quadrant pain and low-grade fever.
-
